Table 2 Clinical characteristics of mCRPC patients (n = 60)
Parameters | AA group No. of patients(%) | Prednisone-alone group No. of patients(%) | P value |
|---|---|---|---|
Age (median, IQR) years | 67(63–76) | 67(62.5~ 74.5) | 0.8 |
ECOG PS | 1.0 | ||
0 | 22(51.2%) | 9(53.0%) | |
1 | 13(30.2%) | 5(29.4%) | |
2 | 8(18.6%) | 3(17.6%) | |
PSA (median, IQR) μg/L | 41.6 (15.9~ 239) | 46.1(38.0~ 92.4) | 0.7 |
Gleason Score | 0.6 | ||
≤ 7 | 15(4.9%) | 7(41.2%) | |
> 7 | 28(65.1%) | 10(58.8%) | |
Metastatic site | |||
Bone metastasis | 42(97.7%) | 17(100%) | 1 |
Lymph node metastasis | 18(41.9%) | 5(29.4%) | 0.4 |
Lung metastasis | 1(2.3%) | 0(0%) | 1 |
The number of bone metastasis | 0.7 | ||
0 | 1(2.3%) | 0(0%) | |
1~ 3 | 13(30.2%) | 4(23.5%) | |
4~ 10 | 11(25.6%) | 3(17.7%) | |
> 10 | 18(41.9%) | 10(58.8%) | |
PSA PFS(percentage) | 23(53.5%) | 17(100%) | |
rPFS(percentage) | 23(53.5%) | 8(47.1%) | |
OS(percentage) | 11(25.6%) | 8(47.1%) | |
Follow-up time (median, IQR) months | 14.2 (7.2–18.4) | 13.8 (9.0–17.4) | |